Indian Journal of Cancer (ISSN 0019-509X), the show window of the progress of oncological sciences in India, was established in 1963. Indian Journal of Cancer is the first and only periodical serving the needs of all the specialties of oncology in India. Its international repute is recognized by its indexing with most bibliographic databases including MEDLINE, Index Medicus, EMBASE and Biological Abstracts.
The journal is official publication of the Indian Cancer Society and Indian Society of Oncology.
The readership has expanded beyond the boundaries of the country. Apart from journal's own website, the internet issue of the journal has been made available with collaboration with Bioline International, Canada. The journal's content from www.bioline.org.br/cn attracts more than 5000 visitors per month, from all over the world. The journal utilizes most advanced tools for its management including an electronic system for manuscript submission and review.
The issues are published Quarterly. Articles can be submitted online from www.journalonweb.com . The journal provides immediate free access to all the published articles. The journal does not charge the authors for submission, processing or publication of the articles
Abstracting and Indexing Information
The journal is registered with the following abstracting partners:
Baidu Scholar, CNKI (China National Knowledge Infrastructure), EBSCO Publishing's Electronic Databases, Ex Libris – Primo Central, Google Scholar, Hinari, Infotrieve, National Science Library, ProQuest, TdNet, Wanfang Data
The journal is indexed with, or included in, the following:
EMBASE/ Excerpta Medica, IndMed, MEDLINE/Index Medicus, Scimago Journal Ranking, SCOPUS, Science Citation Index Expanded, Web of Science
as reported in the 2018 Journal Citation Reports®
(Clarivate Analytics, 2019): 0.429
Wolters Kluwer and Journal/Association are committed to meeting and upholding standards of ethical behavior at all stages of the publication process. We follow closely the industry associations, such as the Committee on Publication Ethics (COPE), International Committee of Medical Journal Editors (ICMJE) and World Association of Medical Editors (WAME), that set standards and provide guidelines for best practices in order to meet these requirements. For a summary of our specific policies regarding duplicate publication, conflicts of interest, patient consent, etc., please visit www.Medknow.com/EthicalGuidelines.asp
Open Access Publication and Creative Commons Licensing
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Wolters Kluwer Medknow provides for long-term digital preservation through two primary partnerships, Portico and CLOCKSS.
Portico is a leading digital preservation service worldwide. The content is preserved as an archival version and is not publically accessible via Portico, but is provided when required under specific conditions, such as discontinuation of the collection or catastrophic failure of the website.
CLOCKSS will enable any library to maintain their own archive of content from Wolters Kluwer Medknow and other publishers, with minimal technical effort and using cheaply available hardware.
Ahead of Print policy
Articles published online under the Ahead of Print model are considered published and can be cited and quoted using the DOI as the reference source. Wolters Kluwer Medknow has a policy that changes will not be made after publication of an article without following accepted procedures for making corrections to the scientific record.
While advertisements are crucial to this journal to be able to keep all content free for everyone, ethical considerations are in place to ensure the integrity of the journal and its content:
- "Pop-up" and "banner" ads appear on a random, rotating basis. The advertiser has no control or input over the pages where their ads appear.
- The Editorial Board has full and final approval over the content of all advertisements.
- Advertisers will never be shown any manuscripts or other content prior to publication.